Nurix Therapeutics, Inc.
NASDAQ:NRIXBiotechnology
+$0.15 today
- Market cap
- $1.54B
- Beta
- 1.87
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$2.68
Volume 2.79M
Average 1.74M
NRIX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Nurix Therapeutics, Inc.NASDAQ: NRIX
Depreciation & Amortization · Q3 FY2026 · quarter ended Aug 2026
Depreciation & amortization declines year over year
Q3 FY2026 depreciation & amortization of $3.62M fell 27.7% year over year, behind the -14.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 6.1% from the prior quarter. Over 3 fiscal years it compounded at +20.4% a year.
Context
- Depreciation & amortization amounted to 22.5% of revenue in FY2025, down 7.7 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -27.7% toward the trailing-twelve-month pace of -14.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 18.86M USD
- Year-over-year change
- +14.8%
- 4-year CAGR
- +32.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-11-30 | 18.86M | +14.8% |
| FY2024 | 2024-11-30 | 16.43M | +20.3% |
| FY2023 | 2023-11-30 | 13.65M | +26.3% |
| FY2022 | 2022-11-30 | 10.81M | +77.7% |
| FY2021 | 2021-11-30 | 6.08M | — |
Depreciation & Amortization vs competitors
How NRIX compares with its peers on the latest reported figures
- NRIX's LTM Aug 2026 depreciation & amortization of $15.87M is the 2nd largest of the 8 companies compared; the peer median is $2.43M.
- Its year-over-year change of -14.3% is the 6th highest of 8, against a peer median of +1.6%.
- Depreciation & amortization amounts to 2.3% of revenue for NRIX, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $18.08M | +31.1% | +19.7% | — | |
| LTM Aug 2026 | $15.87M | -14.3% | +20.4% | 2.3% | |
| LTM Jun 2026 | $8.23M | +1.6% | +40.8% | 7.8% | |
| LTM Mar 2026 | $3.38M | +84.9% | +5.3% | 9.7% | |
| LTM Mar 2026 | $2.43M | +183.7% | — | 3.4% | |
| LTM Mar 2026 | $2.41M | -1.0% | +34.3% | 0.8% | |
| LTM Sep 2026 | $1.79M | -26.2% | +12.4% | — | |
| LTM Mar 2026 | $102K | -2140.0% | -43.3% | 0.0% | |
| Peer median (excluding NRIX) | $2.43M | +1.6% | +16.0% | 3.4% | |
Competitors are the stored peer set for NRIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Nov 2021 | FY2022 Nov 2022 | FY2023 Nov 2023 | FY2024 Nov 2024 | FY2025 Nov 2025 |
|---|---|---|---|---|---|
| Net Income | (117.19M) | (180.36M) | (143.95M) | (193.57M) | (264.46M) |
| Depreciation & Amortization | 6.08M | 10.81M | 13.65M | 16.43M | 18.86M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 15.8M | 28.13M | 33.67M | 33.93M | 37.97M |
| Change in Working Capital | 9.11M | (19.02M) | 20.12M | (18.4M) | (31.6M) |
| Accounts Receivables | (6M) | 6M | 0 | 0 | 0 |
| Inventory | 6.77M | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.59M | 85K | 1.61M | 5.21M | (630K) |
| Other Working Capital | 6.75M | (25.11M) | 18.51M | (23.61M) | (30.97M) |
| Other Non-Cash Items | 1.83M | 636K | (4.87M) | (10.97M) | (10.23M) |
| Operating Cash Flow | (84.37M) | (159.81M) | (81.37M) | (172.58M) | (249.47M) |
| Capital Expenditures | (5.66M) | (12.24M) | (8.4M) | (9.27M) | (14M) |
| Acquisitions (Net) | 102.59M | (39.44M) | 0 | 0 | 0 |
| Purchases of Investments | (348.5M) | (239.37M) | (246.33M) | (707.95M) | (455.69M) |
| Sales of Investments | 245.91M | 278.81M | 323.04M | 459.51M | 617.54M |
| Other Investing Activities | (102.59M) | 39.44M | 0 | 0 | 0 |
| Investing Cash Flow | (108.25M) | 27.2M | 68.3M | (257.71M) | 147.85M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 150.16M | 19.4M | 3.22M | 478.5M | 238.64M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.73M | 97.79M | 0 | 7.17M | 0 |
| Financing Cash Flow | 153.88M | 117.19M | 3.22M | 485.67M | 238.64M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (67K) |
| Net Change in Cash | (38.73M) | (15.42M) | (9.85M) | 55.37M | 137.03M |
| Free Cash Flow | (90.03M) | (172.05M) | (89.77M) | (181.86M) | (263.47M) |
Nurix Therapeutics, Inc.
NASDAQ:NRIX
Intrinsic Alpha fair value
Locked
Current Price
$14.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.